T apentadol is a novel, centrally acting analgesic drug used for treating moderate-to-severe pain in a wide range of patients. [1] [2] [3] [4] It is characterized by a dual mechanism of action: µ-opioid receptor (MOR) agonism and noradrenaline reuptake inhibition (NRI). Both mechanisms have been shown to contribute synergistically to its analgesic effect, thus resulting in potent analgesia in the presence of an opioid-sparing effect. [5] [6] [7] [8] Many experimental and clinical studies demonstrated that the low affinity of tapentadol for MOR is important to reduce the side effects typically associated with opioids such as nausea and vomiting, inhibition of gastrointestinal transit, and constipation. 9, 10 Among opioid side effects related to MOR activation, also immunomodulation has been recognized and discussed extensively. 11, 12 It has been demonstrated previously that the opioid immunosuppressive properties depend on binding to MOR and that most of the immune effects of morphine are lost in MOR knockout mice. 11, [13] [14] [15] [16] [17] [18] [19] Opioids modulate immune function either by interacting directly in the periphery with MOR receptors expressed by lymphocytes and mononuclear phagocytes 20, 21 or activating central MOR that can stimulate hypothalamus pituitary adrenal axis. 22 However, it has been shown that not all opioids exert the same impact on the immune system 11 ; single molecules must be evaluated carefully for their immunomodulating potential. Considering that in clinical practice opioids often are used in immunocompromised individuals, it is important to obtain good pain control by using drugs with low immune impact.
BACKGROUND: Opioid drugs affect immunity, but not all opioid drugs share the same immunomodulatory properties. Tapentadol is an analgesic drug with a dual synergistic mechanism of action: µ-opioid receptor agonism and noradrenaline reuptake inhibition. Weaker µ-opioid receptor agonism combined with noradrenaline reuptake inhibition results in potent analgesia with reduced opioid side effects. We evaluated the impact of tapentadol on splenic cytokine in normal and in hyperalgesia/allodynia mice, comparing it with morphine and reboxetine, a noradrenaline reuptake inhibitor. METHODS: Tapentadol, reboxetine, and morphine were injected subcutaneously into naïve and mice that underwent sciatic nerve chronic constriction injury, and their effect on splenic cytokines (interferon-γ [IFN-γ], interleukin [IL]-2, IL-10, and IL-4) was measured by enzyme-linked immunosorbent assay after acute or chronic treatment. Nociceptive thresholds, thermal hyperalgesia, and allodynia also were assessed. Data were analyzed with 2-way analysis of variance (behavior) or 1-way analysis of variance (cytokines) followed by Bonferroni post hoc test. RESULTS: Primary outcomes of our study were the effects of drugs on splenic cytokines. Our data indicate that acute tapentadol did not modify cytokine production in comparison with animals that received saline, whereas morphine suppressed all the cytokines: saline versus morphine 10 mg/kg (mean difference Among the many regulatory pathways affecting immune responses, it has been demonstrated that they also can be modulated by the autonomic nervous system: catecholamines such as noradrenaline, released by sympathetic fibers innerving primary and secondary lymphoid organs, can modulate immune function by interacting with adrenoreceptors on immune cells. [23] [24] [25] Therefore, tapentadol may affect immune function both by MOR binding and inhibition of NA reuptake. It is important to understand whether these activities, which are moderate at the single target site, are sufficient to modulate immune function; on these bases, we evaluate, for the first time, the impact of acute and chronic tapentadol treatment on splenic cytokine production in naive mice and, to better resemble clinical practice, in mice that underwent chronic constriction injury (CCI) of the sciatic nerve to induce thermal hyperalgesia and mechanical allodynia. The effects of tapentadol are compared with those of morphine, a pure opioid, or reboxetine, a pure noradrenaline reuptake inhibitor.
METHODS

Drugs and Reagents
Tapentadol hydrochloride (20 and 30 mg/kg; Grunenthal GmbH, Aachen, Germany), morphine hydrochloride (5 and 10 mg/kg; Salars, Como, Italy), and reboxetine mesylate hydrate (30 mg/kg; Sigma Aldrich, Milano, Italy) were dissolved in saline and subcutaneously injected (0.1 mL/10 g mouse). Concanavalin A (C5275; Sigma Aldrich, Milano, Italy) was used in vitro at a concentration of 10 μg/mL.
Animals
C57BL6/J male mice (20-25 g ) were used in all the experiments. Animals were kept on a 12-hour light-dark cycle with water and food ad libitum.
All animal care and experimental procedures complied with the International Association for the Study of Pain and European Community (E.C.L358/118/12/86) guidelines and were approved by the Animal Care and Use Committee of the Italian Ministry of Health (Permission 21/2014). All efforts were made to minimize animal suffering. Studies involving animals are reported in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines for reporting experiments involving animals. A total of 160 animals were used for this study.
Acute Treatment
On receipt, animals were randomized in cages of 4 mice each. After 1 week of acclimatization, cages were allocated randomly to the different drug treatments (2 cages for each treatment). Mice were injected subcutaneously with morphine (5 or 10 mg/kg), tapentadol (20 or 30 mg/kg), reboxetine (30 mg/kg), or saline. All the doses were chosen according to the literature or to our previous studies on the immunomodulatory effects of morphine. 26, 27 Nociceptive thresholds were evaluated before drug administration and after 60 and 120 minutes since drug injection by the use of a hot-plate test. At the end of the test (120 minutes), immune cells were collected from the animals.
Evaluation of Nociceptive Thresholds
The hot-plate test was used to assess nociceptive thresholds. 26 The apparatus was set at a temperature of 54 ± 0.5°C. Each animal was placed on the heated surface, and the time interval (seconds) between placement and the simultaneous licking of both fore paws was recorded. 
Chronic Treatment
On receipt, animals were randomized in cages of 4 mice each. After 1 week of acclimatization, cages were allocated randomly to the different drug treatments (2 cages for each treatment). Mice were treated subcutaneously with morphine (10 mg/kg), tapentadol (20 mg/kg), reboxetine (30 mg/kg), or saline for 4 and 7 days. Spleens were collected 24 hours after the last drug injection.
CCI Model
Painful neuropathy was induced in mice by use of the CCI model originally described by Bennett and Xie 28 and adapted for mice as we previously described. 29 To summarize in brief, animals were anesthetized with sodium pentobarbital 60 mg/kg intraperitoneally, and under a dissecting microscope, the right common sciatic nerve was exposed at the level of the mid-thigh proximal to the trifurcation of the nerve; 3 ligatures (4/0 chromic silk; Ethicon) were then loosely tied around it, at about 0.5-mm spacing, until they elicited a brief twitch in the respective hind, with care taken to preserve epineural circulation. 30 Eight animals (2 cages) were chosen randomly, sham operated (sciatic nerve exposure without ligation), and used as controls.
Thermal Hyperalgesia and Mechanical Allodynia Measurement
Thermal hyperalgesia was tested according to the Hargreaves procedure, slightly modified by us for mice, 30 using a plantar test apparatus (Aesthesiometer; Ugo Basile, Comerio, Italy). To summarize, mice were placed in small clear Plexiglas cubicles and allowed to acclimatize. A constant intensity radiant heat source (beam diameter 0.5 cm and infrared heat intensity 20.) was aimed at the mid-plantar area of the hind paw. The time in seconds from initial heat source activation until paw withdrawal was recorded. Mechanical allodynia was assessed with the dynamic plantar Aesthesiometer (Ugo Basile). Animals were placed in a test cage with a wire mesh floor, and the rigid tip of a Von Frey filament (punctate stimulus) was applied to the skin of the mid-plantar area of the hind paw. The filament exerted an increasing force, ranging up to 10 g in 10 seconds, starting below the threshold of detection and increasing until the animal removed its paw. Withdrawal threshold was expressed in grams. Withdrawal thresholds of ipsilateral paws were measured 4 times by a researcher blinded to the treatments. The measurements were performed after 30, 60, and 120 minutes of acute drug treatment and after 4 and 7 days of chronic treatment.
www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA After CCI surgery, 1 mouse from each cage was allocated randomly to one of the following subcutaneous treatments: morphine (10 mg/kg), tapentadol (20 mg/kg), reboxetine (30 mg/kg), or saline. The treatment started 3 days after the induction of neuropathy in the presence of a fully developed thermal hyperalgesia and mechanical allodynia. Spleens were collected 24 hours after the last drug injection and cytokine evaluation was performed after 7 days of chronic pharmacologic treatment.
Splenocyte Cultures
Spleens were removed aseptically from saline and drugtreated animals (naïve or CCI mice) and cells teased from the spleens by the use of 20-gauge sterile needles through an incision made in the spleen cuticle. 4 × 10 6 splenocytes were incubated for 24 hours in the presence of concanavalin A, 10 μg/mL, for interferon (IFN)-γ and interleukin (IL)-2 evaluations or for 48 hours for the evaluations of IL-4 and IL-10.
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Cytokines Evaluation by Enzyme-Linked Immunosorbent Assay (ELISA)
The levels of cytokines were determined by ELISA by the use of ultra-sensitive ELISA kits according to the manufacturer's instructions (e-Bioscience, San Diego, CA). Sensitivity of the kit was 2 pg/mL for IL-2, 15 pg/mL for IFN-γ, 32 pg/mL for IL-10, and 4 pg/mL for IL-4.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism 5 Software (San Diego, CA). Data were tested for equal variance before we chose a statistical analysis.
Data from behavioral tests (MPE, thermal hyperalgesia, and mechanical allodynia) were analyzed by means of 2-way analysis of variance (ANOVA) considering the type of treatment and the time as factors. When we analyzed thermal hyperalgesia and mechanical allodynia in the CCI animals, baseline values, that is, responses before CCI induction, were not included in the 2-way ANOVA. The time points included in the analysis were 3 days after CCI (before drug administration); 30, 60, 120 minutes after the first drug administration; and on days 4 and 7 of drug treatments. Data were tested to find whether an overall significant difference was present for the variables time and drug treatments as well as for time × treatment interaction. If the overall test comparing groups was significant, a Bonferroni test was used for between-group comparisons in the post hoc analysis and analyzed differences in treatments for each time point.
Cytokines results were analyzed with 1-way ANOVA, followed by Bonferroni post hoc test for multiple comparisons. For the primary outcomes, that is, cytokines, we report in the results the difference of means (MD), the lower/ upper 95% confidence interval (CI) values, and the P value.
For all statistical tests, P values < .05 appropriately corrected for multiple comparisons, where needed, were considered to be significant. In particular, when we analyzed thermal hyperalgesia and mechanical allodynia in the CCI animals, we applied a Bonferroni correction for multiple comparisons, and values of P < .025 were considered to be statistically significant. Statistical tests for the 4 cytokines also were Bonferroni corrected for multiple comparisons, and values of P < .0125 were considered significant.
Results are presented as mean ± SD of samples/measures obtained from 8 mice. The group size was chosen on the basis of the results obtained in our previous studies on the effect of morphine on cytokines, considering an expected difference in means of 40%, SD of 25%, number of treatments 4 to 6, power = 0.95, and α = 0.05.
RESULTS
Effect of Acute Treatment on Nociception and Cytokines in Naive Animals
The antinociceptive responses evaluated 60 and 120 minutes after drug administration are shown in Figure 1 and are expressed as %MPE. Two-way ANOVA analysis found a significant difference among treatments (P < .001), no differences for the time factor, and a significant treatment × time interaction (P < .05). Post hoc comparison (Bonferroni test) revealed that at both 60 and 120 minutes after treatments, all doses of tapentadol and morphine were different from saline (P < .001). Five mg/kg morphine and 20 mg/kg tapentadol exerted a similar antinociceptive effect (% MPE ≈ 50) without any significant difference between the 2 drugs. Greater doses of 10 mg/kg morphine and of 30 mg/kg tapentadol resulted in a significant increase of the antinociceptive thresholds in comparison with the respective lower doses (P < .001), reaching %MPE of approximately 90% and 70%, respectively. The antinociceptive effect of morphine 10 mg/kg was significantly greater than that of tapentadol 30 mg/kg (tapentadol versus morphine 60/120 minutes: MD [95% CI] = 24.4 [13.28, 35 .52]/17.40 [6.28, 28 .52], P < .001). In contrast, at the dose of 30 mg/kg the pure noradrenaline reuptake inhibitor reboxetine was unable to induce any significant acute analgesic effect at any evaluation point. We also tried a very high dose, equal to 100 mg/kg, of reboxetine, but we did not achieve any significant analgesic effect, observing, on the contrary, adverse behavioral effects in animals (data not shown). Figure 2C .
In contrast to morphine, neither tapentadol, at any tested dose, nor reboxetine had any significant effect on the levels of all these cytokines ( 
Chronic Drug Effect on Splenic Cytokines
The levels of splenic cytokines were evaluated after 4 and 7 days of chronic treatment, 24 hours after the last drug injection, and results are reported in Figure 3 . For each cytokine, results were analyzed with 1-way ANOVA analysis, followed by Bonferroni post hoc test for all treatment group comparisons. Chronic administration of morphine showed an immunosuppressive effect, significantly decreasing, after 4 days of treatment, the production of all the cytokines in comparison with saline-treated animals (saline versus morphine: IFN- 16 .24], P < .01, whereas its effect on the other cytokines disappeared, probably because tolerance was starting to develop. The immune profile of tapentadol was different from that of morphine but similar to that of the pure noradrenaline reuptake inhibitor reboxetine. Tapentadol and reboxetine never modulated the production of IFN-γ, IL-2, IL-10, and IL-4 at any time during the evaluation, because no significant difference was ever observed with saline-treated animals. 
Effect of Drugs on Mechanical Allodynia and Thermal Hyperalgesia in CCI Animals
All drugs were injected beginning 3 days after CCI and their effect on mechanical allodynia and thermal hyperalgesia was monitored 30, 60, and 120 minutes after the first drug injection (acute effect) and after 4 and 7 days of chronic treatment, 24 hours after the last injection. Figure 4A reports mechanical allodynia; thermal hyperalgesia is shown in Figure 4C . Twoway ANOVA showed a significant difference in both allodynia and hyperalgesia responses among treatments (P < .001), time points (P < .001), and a significant interaction (P < .001). Post hoc comparison (Bonferroni t test) was applied, and for clarity, the statistical analysis and the significant differences among drug treatments (for each time points) are reported in Figure 4B and D rather than in the graphs.
As shown in Figure 4A , and reported in Figure 4B , the antiallodynic effect of tapentadol was similar to that of morphine. Around 60 minutes after drug injection, the withdrawal thresholds of tapentadol and morphine-treated mice reached values that remained constant for the duration of the chronic treatment. In contrast, the acute antihyperalgesic effect of tapentadol ( Figure 4C and D) was stronger but shorter than that of morphine. When tapentadol was injected chronically, its antihyperalgesic effect increased over time, and at 7 days of treatment, its antihyperalgesic effect was even more evident than that of morphine (morphine versus tapentadol: MD [95% CI] = 4.65 [2.8, 6 .54], P < .001).
The profile of the pure noradrenaline reuptake inhibitor is quite different from that of the 2 other drugs; in fact, acute reboxetine was unable to improve either allodynia or hyperalgesia. After 4 days of chronic treatment, however, a significant antiallodynic and antihyperalgesic effect began to be evident. The antiallodynic effect remained mostly stable over time, although it was lower than that of the 2 other drugs. The antihyperalgesic effect of reboxetine was similar to that of morphine and lower than tapentadol after 7 days of treatment.
Effect of Drugs on Splenic Cytokines in CCI Animals
Cytokines were evaluated 10 days after CCI surgery corresponding to 7 days of chronic pharmacological treatments. The results were analyzed with 1-way ANOVA, followed Results were analyzed with 1-way analysis of variance followed by Bonferroni post test for multiple comparisons considering all treatments. In the figure, the significance versus saline-and versus morphine-treated mice is reported. **P < .01, ***P < .001 versus salinetreated mice at the same time point; #P < .0125, ##P < .01, ###P < .001 versus morphine-treated mice at the same time point.
by Bonferroni post hoc test for multiple comparison. As shown in Figure 5 The effect of morphine (10 mg/ kg), tapentadol (20 mg/kg), and reboxetine (30 mg/kg) on mechanical allodynia (A) and thermal hyperalgesia (C) that developed as a consequence of sciatic nerve chronic constriction injury (CCI) was examined. Drugs were injected subcutaneously starting from day 3 after CCI. Antiallodynic and antihyperalgesic effects were measured 30, 60, and 120 minutes after the first drug injection (acute effect) and after 4 and 7 days of daily chronic treatment (corresponding to 7 and 10 days after CCI), 24 hours after the last injection. Data are means ± SD of 8 animals. Results were analyzed with 2-way analysis of variance, considering the type of treatment and the time as factors, followed by Bonferroni post test for multiple comparisons. In the graph, the significance versus sham mice is reported (*P < .025, **P < .01, ***P < .001). Detailed statistical significance among the 3 different drug treatments at each time point is reported in panels B and D (*P < .05, **P < .01, ***P < .001).
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DISCUSSION
This study assessed the effects of the analgesic drug tapentadol on the immune system. Tapentadol, because of its dual mechanism of action, MOR agonism, and NRI, is considered as the first representative of a new class of analgesics, MOR-NRI. [5] [6] [7] [8] Both mechanisms synergistically contribute to the final analgesic effect, allowing the drug to exert a moderate activity at the 2 target sites resulting in an opioidsparing effect in the presence of a high analgesic efficacy. 31 As consequence, tapentadol shows an improved tolerability profile as compared with classic opiates. 9, 10 It is accepted that opioids can affect immune function and that not all opioids exert the same immunomodulatory properties. 11, 12, 14, 15, 17 Opioids modulate immune responses by directly interacting with opioid receptors expressed on peripheral immune cells or by central mechanisms activating the hypothalamic-pituitary-adrenal axis and the autonomic nervous system. On the other hand, catecholamines such as noradrenaline, released by sympathetic fibers innerving primary and secondary lymphoid organs, can modulate immune function by interacting with adrenoreceptors on immune cells. [23] [24] [25] Here, we focused on the capacity of tapentadol to affect cytokine production by splenic cells. Spleen cells include a mixed cell population of T cells, B cells, and a low fraction of macrophages; we activated T cells present in splenocyte cultures by using the T-cell polyclonal activator concanavalin-A. 26 The results obtained 2 hours after acute tapentadol administration show that the immune effects of the drug are different from those of morphine: our data, in fact, confirm the well-known dosedependent immunosuppressive properties of morphine on cytokine production and describe for the first time a neutral effect of acute tapentadol, suggesting that neither the MOR nor the NRI component of the drug are sufficient to affect the immunity after a single-drug injection. 32 It is interesting to note that after acute administration, reboxetine was not able to exert any antinociceptive effect, Figure 5 . Chronic drug effect on splenic cytokines in CCI mice. The effect of CCI and drug treatment on splenic cytokines was measured by enzyme-linked immunosorbent assay. Chronic treatment with morphine (10 mg/kg), tapentadol (20 mg/kg), and reboxetine (30 mg/kg) was started 3 days after CCI. Spleen cells were collected after 7 days of chronic treatment, 24 h after the last injection (day 10 after CCI). Cells were stimulated in vitro with concanavalin-A (10 μg/mL) for 24 (IFN-γ and IL-2, panels A and B) or 48 hours (IL-10 and IL-4, panels C and D). Data are means ± SD of samples obtained from 8 mice. Results were analyzed with 1-way analysis of variance followed by Bonferroni post test for multiple comparisons considering all groups. In the figure, significance versus sham, versus CCI, and versus CCI+ morphine mice is reported. *P < .0125, **P < .01, ***P < .001 versus sham; °P < .0125, °°°P < .001 versus CCI; ##P < .01, ###P < .001 versus CCI+ morphine mice.
that is, instead well evident after tapentadol since it acts as MOR agonist and NRI in a synergic way. The double mechanism of tapentadol also plays a crucial role when the drug is injected acutely into CCI mice, since it shows a rapid and strong antihyperalgesic efficacy that makes it different from both morphine and reboxetine. In chronic experiments, we choose to compare the dose of 20 mg/ kg of tapentadol with that of 10 mg/kg of morphine. Although these doses, in normal animals, show a different analgesic profile after acute administration (hot-plate test), in the presence of a hypersensitivity condition, they become equianalgesic; this finding is in accordance with the literature that describes a greater potency of tapentadol in neuropathic pain models. 31 It is interesting to note that the antihyperalgesic effect of chronic treatment with tapentadol and reboxetine appears to be delayed than morphine. Descending inhibitory/facilitatory pathways are altered during neuropathic pain progression, 33 and therefore, stimulation of the noradrenaline descending pathways may be particularly effective. It can be hypothesized that in our CCI model, the noradrenergic activity of tapentadol can be exploited fully when this system is modified. It is important to emphasize that the antihyperalgesic and the antiallodynic effect exerted by the different drugs also persists 24 hours since the last drug injection, suggesting a long-lasting modulatory effect on neuropathy-induced alterations. We also show that after chronic treatment, both tapentadol and reboxetine did not affect cytokine production at any investigational time point. In contrast to tapentadol and reboxetine, the immunosuppressive effects of morphine on all cytokines, already evident after acute injection, continue to be present after 4 days of chronic treatment and undergo tolerance for the different cytokines over time.
The different immunopharmacologic profiles of morphine and tapentadol once again demonstrate that MOR activation exerted by tapentadol is not sufficient to modulate cytokine production. Sympathetic nerve fibers richly innervate lymphoid organs, 34, 35 and catecholamines play a significant role in immune system regulation. 23, 25, 36 Most immune cells 37 express β2-adrenoreceptor, so locally released noradrenaline or circulating catecholamines may affect many immune functions like traffic, circulation, proliferation, cytokine production, and cytotoxic activity mainly via β2-adrenoreceptor signaling. 23, 25, 36 In our experimental conditions, however, we demonstrated that noradrenergic stimulation with reboxetine alone does not appear to be sufficient to modulate immunity. Our results clearly demonstrate that the synergy of the 2 mechanisms of action of tapentadol that play a crucial role in analgesia does not hold true for the immunosuppressive properties.
Considering that pain is a stressful condition capable of affecting immune function by activating both the hypothalamic-pituitary-adrenal and autonomic system, 38 we tested the immunomodulatory properties of tapentadol in an accepted experimental model of neuropathic pain. Our results show a CCI-mediated general immunodepression, resulting in a decrease in the production of all the cytokines 10 days after surgery. After 7 days of chronic pharmacologic treatment, in the presence of a similar antihyperalgesic effect of the 3 drugs, tapentadol and reboxetine restored IL-10 and IL-4 cytokines, whereas in morphine-treated mice, the levels of these cytokines remain reduced. This protective effect can be explained by the good antihyperalgesic and antiallodynic effect of tapentadol together with its neutral activity on the production of these cytokines, in contrast to morphine, which possesses intrinsic suppressive activity. Interestingly, however, a full protective effect is observable only for IL-4 and IL-10 and not for IFN-γ and IL-2. At the moment, we do not have a convincing explanation for these results. IL-10 and IL-4 are produced mainly by T-helper 2 lymphocytes, whereas IL-1 and IFN-γ are prototype type 1 cytokines. It can be hypothesized that the T-helper 1 and T-helper 2 functional subsets may differ in their susceptibility to the presence of painful symptoms and to drugs.
The clinical relevance of opioid-induced immunomodulation is still a matter of debate, 11, 39, 40 and the long-term effects of opioids on immune system have not been studied adequately in humans. 12 However, there are clearly some moments and situations when the risks derived from opioid-induced immunosuppression may become relevant. A risk situation is during the perioperative period, because it is well known that anesthesia and surgery affect the immune response 41 ; in this situation, the choice of analgesics devoid of immunosuppressive activity has been shown to be especially indicated.
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A greater vulnerability of the immune system is present in the elderly individuals, whose immune systems undergo developmental changes as the result of increasing age. 42 The opioid-induced immunosuppression obviously can be dangerous in already-immunocompromised patients, such as HIV-positive patients, or with the concomitant use of other immunosuppressive drugs such as chemotherapy or glucocorticoids. 43 The specific restorative effect of tapentadol on T-helper 2 cytokines IL-10 and IL-4 in the CCI animals is particularly interesting and may be of particular clinical relevance. In fact, these cytokines play an important protective role in chronic inflammatory pathologies, where an imbalance toward T-helper 1 cytokines is often present. 44 Therefore, we can speculate that tapentadol may represent a good choice for treating chronic pain with an inflammatory component.
In conclusion, our results describe a neutral effect of acute and chronic tapentadol on cytokine production, thus suggesting that the synergy of the 2 mechanisms of action of tapentadol that play an important role in analgesia does not hold true for the immunosuppressive properties, and further confirming in preclinical studies that the drug possesses features that are different from those of morphine. E DISCLOSURES Name: Silvia Franchi, PhD. Contribution: The author performed experiments, performed statistical analysis, and wrote the manuscript. The author approved the final version of manuscript. Name: Giada Amodeo, PhD. Contribution: The author performed experiments. The author approved the final version of manuscript. Name: Marta Gandolla, PhD.
